Researchers indicate polyurethane catheters, such as those used in Bard PowerPort implants, often lead to early device failure and infections.
Lawsuit over the Angiodynamics port catheter raises allegations similar to those found in hundreds of Bard PowerPort lawsuits, indicating that device was defectively designed and increases the risk of infections, other injuries.
At least 10 patient injuries and one death have been reported in connection to the Arrow QuickFlash catherization kit recall.
Judge compared Bard PowerPort lawsuits to IVC filter litigation, where the majority of cases were filed more than 18 months after the claims were consolidated into a MDL
Of the 25 Bard chemo port devices on the market, at least 15 have been identified in lawsuits filed over failures, infections and other complications among individuals who received the implantable port catheter.
U.S. JPML has confirmed that Bard PowerPort infection lawsuits raising alternative theories of causation, such as reservoir defects, should be included in the federal MDL established last year in the District of Arizona
The outcome of the early bellwether test trials could impact the average Bard Power Port lawsuit settlement amounts the manufacturer may need to pay to avoid hundreds of claims being remanded for individual trials.
MDL panel will hear oral arguments on Jan. 25, to determine whether port reservoir defect lawsuits should be combined with other Bard port lawsuits being pursued over problems with the catheter material.
Judge has approved a new streamlined process for plaintiffs to file Bard Power Port lawsuits directly in the U.S. District Court for the District of Arizona, where the federal litigation is centralized.
The presiding judge has determined that six Bard PowerPort lawsuits will ultimately be chosen for the first bellwether trials.
